Atea Pharmaceuticals, Inc. (AVIR)
NasdaqGS · USD · Healthcare · Biotechnology
$4.16 (+2.97%) as of
Key statistics
- Market cap
- 333.65M
- Forward P/E
- -2.81
- EPS (TTM)
- -2.0300
- Dividend yield
- 0.00%
- 52-week range
- 2.8700 – 6.4500
- Beta
- 0.39
- Profit margin
- 0.00%
- Analyst target
- $8.50
- Volume
- 251.09k
About Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Boston, MA, United States
- Employees
- 55
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.